IDSA recommends shorter antibiotic courses for adults with cUTIs who show clinical improvement on effective therapy.
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and ...
This guide deconstructs the pathophysiology of UTIs, exploring the anatomical risks in women, and the efficacy of antibiotic regimens ...
Exblifep is a combination product that consists of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. The Food and Drug Administration (FDA) has approved Exblifep ...
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation ...
intravenous antibiotics Cefepime-enmetazobactam may be more effective than piperacillin-tazobactam in treating complicated UTI and acute pyelonephritis caused by organisms that produce ...
Carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa are a global threat to antimicrobial resistance and may be causative pathogens in cUTI. Cefepime-taniborbactam ...
Researchers from Shaanxi Panlong Pharmaceutical Group Co. Ltd., Shaanxi Pioneer Biotech Co. Ltd. and affiliated organizations presented the discovery and preclinical characterization of novel ...
A young male cadaveric kidney transplant developed delayed graft function. In addition to fever, serial allograft biopsies revealed progressive infiltration of polymorphonuclear leukocytes. After ...
"The five factors with the highest odds of developing APN included obstructive and reflux uropathy, presentation to an acute care facility, urinary retention, history of UTI, and renal comorbidities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback